Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Porfiromycin as Adjuvant to Radiotherapy in Head and Neck Cancer
NCT02183246Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2000
- Primary completion
- Dec 2000
01
Overview
A Phase 3 trial of porfiromycin in head and neck squamous cell carcinoma (HNSCC), sponsored by Boehringer Ingelheim. Started May 2000; status: terminated.
02
Drugs
porfiromycin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02183246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183246.